

## Disclosures

### Personal Commercial (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Edwards Lifesciences	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Invasive CV Angio and Interventions</i>
Medtronic	Consultant Fees/Honoraria	Modest (< \$5,000)	
X-dot Medical	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (30)

Trial Name	Trial Sponsor	Trial Funding Source
MitraClip REPAIR MR Study	Abbott Medical Devices	
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation (ENVISION)	Abbott Medical Devices	
Portico Next Generation Approval Study	Abbott Medical Devices	
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function (PROTECT IV)	Abiomed Inc.	
Intensive Lipid Monitoring Following Percutaneous Coronary Intervention	Amgen Inc.	
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study	Ancora Heart, Inc.	
CHAMPION-AF Clinical Trial (CHAMPION-AF)	Boston Scientific Corporation	
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement	Boston Scientific Corporation	
VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS) (VITALYST EFS)	Boston Scientific Corporation	
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions (MAGICAL ISR)	Concept Medical Inc.	
Edwards PASCAL CLASP IID/IIIF Pivotal Clinical Trial (CLASP IID/IIIF)	Edwards Lifesciences	
TRISCEND II Pivotal Trial	Edwards Lifesciences	
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve	Edwards Lifesciences	
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR (PROGRESS)	Edwards Lifesciences	
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves	Edwards Lifesciences	
Edwards PASCAL TrAnScatheter Valve RePair System in Tricuspid Regurgitation (CLASP TR) Early Feasibility Study	Edwards Lifesciences	
Clinical Study of Edwards Cardioband FIT Valve Repair System	Edwards Lifesciences	
The JenaValve ALIGN-AR Pivotal Trial (ALIGN-AR)	JenaValve Technology, Inc	
Laminar LAAX Pivotal IDE Study	Laminar, Inc.	
The Early Feasibility Study of the Transcatheter Tricuspid Valve Replacement System Transfemoral System	Medtronic Cardiovascular	
Optimize PRO Study	Medtronic Cardiovascular	
Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study	Medtronic Cardiovascular	

Trial Name	Trial Sponsor	Trial Funding Source
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. (APOLLO)	Medtronic Cardiovascular	
A Prospective, Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation - TRICAV Trial	P+F Products + Features USA Inc.	
The ShortCut™ Study Protocol	Pi-Cardia	
The PROTEMBO Trial	Protembis GmbH	
Three-dimensional (3D) Holographic Display for Structural and Congenital Heart Disease Ultrasound Based Procedures	Real View Imaging Ltd.	
The TRICURE EFS TRICares Topaz Transfemoral TRICUspid Heart Valve REplacement System Early Feasibility Study	Tricare	
TRICares Topaz Transfemoral Tricuspid Heart Valve Replacement System First In Human Trial (TRICURE)	Tricare	
PerQseal® IDE Clinical Study - PATCH	Vivasure Medical Limited	

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 6/23/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement | Signed on 6/23/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo | Signed on 6/23/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement | Signed on 6/23/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.